

HEPATITIS B IS NOW A ROUTINE AGE-BASED VACCINE AND **OVER 130 MILLION ADULTS ARE ELIGIBLE FOR PROTECTION**^{1,2*}

HEALTHCARE PROVIDERS AND PATIENTS NEED TO KNOW WHY HEPATITIS B PREVENTION IS IMPORTANT



cases worldwide are due to hepatitis B^{3,4}

On average in the US, there are 42,000 new liver cancer cases and 30,000 deaths each year; not all cases are hepatitis B-related. 4†



Chronic hepatitis B infection can lead to^{5,6}:

- Liver cancer
- Liver transplant
- Cirrhosis
- Death

For most people, the hepatitis B virus clears on its own. But for those who do not clear the virus, it can cause liver cancer. From 2018–2022, there were an estimated 13,000–21,000 cases of acute hepatitis B annually; some may progress to chronic hepatitis B and potentially life-threatening consequences.^{7,8}



3 OF 4 ACUTE HEPATITIS B CASES IN 2022 OCCURRED IN PEOPLE WITH NO REPORTED RISK FACTORS - AND IT MAY BE DIFFICULT TO PREDICT WHO CAN GET HEPATITIS B^{5,7}

ACIP'S UNIVERSAL HEPATITIS B VACCINATION RECOMMENDATION 1

19-59 YEAR OLDS

SHOULD RECEIVE HEPATITIS B VACCINATION

≥60 YEAR OLDS

WITH RISK FACTORS:* **SHOULD** RECEIVE VACCINATION

WITHOUT KNOWN RISK FACTORS: **MAY** RECEIVE VACCINATION

ROUTINELY IDENTIFY ELIGIBLE ADULT* PATIENTS AND STRONGLY RECOMMEND HEPATITIS B VACCINATION TODAY

RECOMMENDATION EXAMPLE

Based on your age, you may be eligible for a hepatitis B vaccine. 1,9,10
Hepatitis B infection can be serious and may lead to liver cancer, but it is preventable by vaccination. 6
It's important you get started today.

For most people, the hepatitis B virus clears on its own. But for those who do not clear the virus, it can cause liver cancer. From 2018–2022, there were an estimated 13,000–21,000 cases of acute hepatitis B annually; some may progress to chronic hepatitis B and potentially life-threatening consequences.^{7,8}

 $^{\rm t}$ Estimates for 2024 per the Surveillance, Epidemiology, and End Results Program (SEER) data set. $^{\rm 4}$

ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention.

References: 1. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. 2. Data on file. Dynavax Technologies Corporation. Flow model for universal hepatitis B vaccination (version 4.5) assumptions. May 24, 2021. 3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-943. 4. National Cancer Institute. Cancer stat facts: liver and intrahepatic bile duct cancer. Accessed July 12, 2024. https://seer.cancer.gov/statfacts/html/livibd.html 5. Centers for Disease Control and Prevention. Hepatitis B basics. Accessed June 13, 2024. https://www.cdc.gov/hepatitis-b/about/ 6. Doshani M. Evidence to recommendations framework: should all HepB-unvaccinated adults receive hepatitis B vaccination? Presented to ACIP; September 29, 2021. 7. Centers for Disease Control and Prevention. Availability of information on risk behaviors or exposure associated with reported cases of acute hepatitis B – United States, 2022. Accessed August 2, 2024. https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-b/figure-2.7.htm 8. Centers for Disease Control and Prevention. Number of reported cases* and estimated infections* of acute hepatitis B – United States, 2015–2022. Accessed May 28, 2024. https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-b.htm 9. Centers for Disease Control and Prevention. Adult immunization schedule by age. Accessed June 13, 2024. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html 10. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recom



^{*}As of April 2022, the ACIP recommends hepatitis B vaccination for all adults aged 19–59 years and adults aged ≥60 years with hepatitis B risk factors. Adults aged ≥60 years without known risk factors may receive hepatitis B vaccination. Please refer to the hepatitis B vaccination guidelines noted in the MMWR publication for the specific risk factors for hepatitis B. This recommendation applies to adults who have not received a complete hepatitis B vaccine series in their lifetime.¹